Axogen Inc Aktie
?
Deine Einschätzung
Was spricht für und gegen Axogen Inc in den nächsten Jahren?
Pro
Kontra
Rendite von Axogen Inc im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Axogen Inc | -1,12 % | 8,25 % | 24,77 % | 229,61 % | 49,50 % | 661,09 % | 203,33 % |
| Fluidigm Corp. | 0,00 % | -11,68 % | -17,69 % | -41,26 % | -42,92 % | -75,80 % | -89,06 % |
| Accuray Inc. | -0,33 % | -0,89 % | 4,86 % | -79,34 % | -64,12 % | -91,47 % | -92,07 % |
| Pacific Biosciences of California Inc. | 2,20 % | -2,55 % | -25,46 % | -10,49 % | -32,83 % | -90,30 % | -96,01 % |
Kommentare
Der Beitrag wird untersucht
Der Beitrag wird untersucht
News
AxoGen Q2 Earnings Call Highlights
Key Points
- Interested in AxoGen, Inc.? Here are five stocks we like better.
- Strong revenue growth: AxoGen’s second-quarter revenue rose 23.1% year over year to $69.7 million, driven largely by
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
DAFNA Capital Management cut its holding in Axogen (NASDAQ:AXGN) by 265,456 shares in the fourth quarter, an estimated $6.53 million trade based on quarterly average pricing, according to a February




